Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 8/20 | 0.62 |
| ▸ | CTSB | P07858 | 3/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | GRB2 | P62993 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455247 | 0.91 | CAPN1 (0.52) | CAPN1CTSBOPRM1GRB2XIAP | |
| SCHEMBL16488741 | 0.91 | CAPN1 (0.62) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL17229184 | 0.91 | CAPN1 (0.62) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL29396765 | 0.91 | CAPN1 (0.52) | CAPN1CTSBOPRM1GRB2XIAP | |
| SCHEMBL14672864 | 0.90 | CAPN1 (0.64) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL14682322 | 0.90 | CAPN1 (0.64) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL20958599 | 0.90 | CAPN1 (0.64) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL14672865 | 0.90 | CAPN1 (0.64) | CAPN1CTSBOPRM1GRB2 | |
| SCHEMBL20477645 | 0.89 | CAPN1 (0.60) | CAPN1CTSBOPRM1OPRD1OPRK1 | |
| SCHEMBL14673292 | 0.89 | CAPN1 (0.60) | CAPN1CTSBOPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431514-A | Polypeptide derivative with triple targeting agonism of GCGR, GIPR and GLP-1R | 南京知和医药科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4622997-A2 | MELANOCORTIN AND GLP-1 RECEPTOR AGONISTS AND METHODS OF USE | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20240100126-A1 | Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug | I2O THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | SHENZHEN TURIER BIOTECH CO., LTD (CN) | 2023-06-15 | — | — | US | disclosed |
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | SHENZHEN TURIER BIOTECH CO., LTD. | 2022-08-23 | — | — | US | disclosed |
| US-20170298112-A1 | PEPTIDE-OLIGOUREA FOLDAMER COMPOUNDS AND METHODS OF THEIR USE | UREKA SARL (FR) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183310-A1 | Polypeptide Compounds and Use Thereof in the Prevention or Treatment of Diabetes or Diabetic Complications | IAPP, PNLIP, DPP4 | CAPN1 2127/4885CTSB 110/4885OPRM1 656/4885 |
| US-11419918-B2 | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide | GCGR, GLP1R, GIPR | CAPN1 2190/4885CTSB 751/4885OPRM1 897/4885 |
| US-20170298112-A1 | PEPTIDE-OLIGOUREA FOLDAMER COMPOUNDS AND METHODS OF THEIR USE | IAPP, OTC, OAT | CAPN1 3289/4885CTSB 2260/4885OPRM1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.